Drug prescribing pattern in ulcerative colitis in a tertiary care hospital: an observational study

Mukunda Narayanareddy, Eesha B. R., Tara V. Shanbhag, Smita Shenoy


Background: Ulcerative colitis (UC) is an inflammatory disease of colon and rectum of uncertain etiology. The clinical course of UC is marked by exacerbations and remissions. Furthermore there is limited data available on the management of ulcerative colitis from India. Hence, the present study was undertaken to study the drug prescribing pattern in ulcerative colitis.

Methods: A retrospective case record based observational study was done at Kasturba Hospital, Manipal, India from 1st January 2009 to 31st December 2010. Patients diagnosed to have UC during our study period based on clinical, endoscopic and histopathological evidence were included in the study. SPSS 17 software package was used for statistical calculations. Descriptive statistics was used to analyze the data.

Results: The total number of patients diagnosed to have UC during our study period was 83.The peak incidence of disease was in the age group of 30-39 years and it was more common in males. The prescription rate of aminosalicylates, glucocorticoids and immunosuppressants were 96.3, 54.3, and 18.5% respectively. Mesalamine, prednisolone, and azathioprine were the commonly prescribed drugs in each class. The commonly prescribed treatment regimen was combination of aminosalicylates with glucocorticoids (43.2%).

Conclusions: Ulcerative colitis was more common in males. Aminosalicylates were the commonly prescribed drugs and a combination of aminosalicylate and steroid was frequently used regimen in our study.


Ulcerative colitis, Drug prescribing pattern, Aminosalicylates, Immunosuppressants, Glucocorticoids

Full Text:



Goligher JC. Ulcerative colitis. In: Surgery of the Anus, Rectum and colon. 3rd edition. London, Bailliere Tindal; 1977:843-1012.

Calkins BM, Lilienfeld AM, Garland CF, Mendeloff AI. Trends in the incidence rates of ulcerative colitis and Crohn’s disease. Dig Dis Sci. 1984;29:913-20.

Ouyang Q, Tandon R, Goh KL, Pan G, Fock KM, Fiocchi C, et al. Management consensus on inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol. 2006;21(12):1772-82.

Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol. 2006;12(38):6102-8.

Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52(11):1587-90.

Narayanareddy M, Shanbhag V, Shanbhag TV, Bhat G, Shenoy S, Gowda A. A retrospective study of the drug prescribing pattern in crohn’s disease (CD) in a tertiary care hospital. Int J Pharm Sci Rev Res. 2013;20(1):95-9.

Sood A, Midha V, Sood N, Puri S, Kaushal V. Profile of ulcerative colitis in a North Indian hospital. J Indian Acad Clin Med. 2000;5(2):124-8.

Osterman MT, Lichtenstein GR. Ulcerative colitis. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and liver disease. 9th ed. Philadelphia, Elsevier. 2010:1975-2013.

Tandon BN, Mathur K, Mohapatra LN, Tandon HD, Wig KL. A study of the prevalence and clinical pattern of non-specific ulcerative colitis in Northern India. Gut. 1965;6:448-53.

Chuttani HK, Nigam SP, Sama SK, Dhanda PC, Gupta PS. Ulcerative colitis in the tropics. Br Med J. 1967;4:204-7.

Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology. 2009;137:502-11.

Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23.

Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940-87.